Skip to main content

Barrington Upgrades Haemonetics To Outperform, $70 PT

Joe Young

August 03, 2011 9:09am Comments

Barrington Research has upgraded Haemonetics (NYSE: HAE) from Perform to Outperform and has established a $70 price target.

© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

View Comments and Join the Discussion!

View the discussion thread.

Posted-In: Barrington Research Upgrades Price Target Analyst Ratings

Need analyst data?
Click here to see licensing options.

Latest Ratings

View the Latest Analytics Ratings

1	VRTX: Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago W...
2	BPOP: How Is The Market Feeling About Popular?
3	$BTC, $SOL: Bitcoin Stuck Below $118,000 As Ethereum, XRP, Dogecoin Extend...
4	SBET, TSLA: 10 Consumer Discretionary Stocks Whale Activity In T...
5	VZ, WMT: 3 Dividend Bargains For The Rest Of 2025
6	GOOG, GOOGL: Direxion's GOOGL-Focused Bull...
7	VOO: Trump's Fed Pick? He'...

1	NVDA: Nvidia's Jensen Huang Charms China With AI Diplomacy as Tariff Tensions...
2	MP, AAPL: Acquisition Buzz, Legal Battles And Tim Cook's Balancing Act: T...
3	Trump's Tariff Threat, Inflation Dynamics And Federal Reserve U...
4	Bolsonaro's Restraining Order, Gates' TB Warning, And Late...
5	'What Worked for You 5 Or 10 Years Ago May Not Be The Right Str...
6	A Potential Investor Reached Out To Small Business Owners Asking, &#...
7	Should My 80-Year-Old Dad and 65-Year-Old Mom Turn Their $687,000 Ne...